Heterogeneity of BCSCs contributes to the metastatic organotropism of breast cancer

被引:21
|
作者
Wang, Cenzhu [1 ]
Xu, Kun [1 ]
Wang, Runtian [1 ]
Han, Xin [2 ]
Tang, Jinhai [3 ]
Guan, Xiaoxiang [1 ]
机构
[1] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Sch Med & Holist Integrat Med, Nanjing 210023, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Dept Gen Surg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Metastatic organotropism; Breast cancer stem cell; Heterogeneity; Seed and soil; CELL MARKERS CD44; STEM-LIKE CELLS; SELF-RENEWAL; PROMOTES; ALDH1; EXPRESSION; CD24; TRANSITION; PLASTICITY; PHENOTYPE;
D O I
10.1186/s13046-021-02164-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is one of the most-common female malignancies with a high risk of relapse and distant metastasis. The distant metastasis of breast cancer exhibits organotropism, including brain, lung, liver and bone. Breast cancer stem cells (BCSCs) are a small population of breast cancer cells with tumor-initiating ability, which participate in regulating distant metastasis in breast cancer. We investigated the heterogeneity of BCSCs according to biomarker status, epithelial or mesenchymal status and other factors. Based on the classical "seed and soil" theory, we explored the effect of BCSCs on the metastatic organotropism in breast cancer at both "seed" and "soil" levels, with BCSCs as the "seed" and BCSCs-related microenvironment as the "soil". We also summarized current clinical trials, which assessed the safety and efficacy of BCSCs-related therapies. Understanding the role of BCSCs heterogeneity for regulating metastatic organotropism in breast cancer would provide a new insight for the diagnosis and treatment of advanced metastatic breast cancer.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Comparative transcriptome analysis of metastatic heterogeneity in a mouse model of breast cancer
    Ionkina, Anastasia A.
    Balderrama-Gutierrez, Gabriela
    Phan, Steve Huy
    Mortazavi, Ali
    Prescher, Jennifer A.
    CANCER RESEARCH, 2020, 80 (16)
  • [43] Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
    Montemagno, Christopher
    Pages, Gilles
    CANCERS, 2020, 12 (04)
  • [44] Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets
    Liang, Yiran
    Zhang, Hanwen
    Song, Xiaojin
    Yang, Qifeng
    SEMINARS IN CANCER BIOLOGY, 2020, 60 : 14 - 27
  • [45] Heterogeneity of Circulating Tumor Cells in Breast Cancer: Identifying Metastatic Seeds
    Menyailo, Maxim E.
    Tretyakova, Maria S.
    Denisov, Evgeny V.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (05)
  • [46] BREAST-CANCER HETEROGENEITY - EVALUATION OF CLONALITY IN PRIMARY AND METASTATIC LESIONS
    SYMMANS, WF
    LIU, JG
    KNOWLES, DM
    INGHIRAMI, G
    HUMAN PATHOLOGY, 1995, 26 (02) : 210 - 216
  • [47] Heterogeneity of Metabolic Response to Systemic Therapy in Metastatic Breast Cancer Patients
    Huyge, V.
    Garcia, C.
    Alexiou, J.
    Ameye, L.
    Vanderlinden, B.
    Lemort, M.
    Bergmann, P.
    Awada, A.
    Body, J-J
    Flamen, P.
    CLINICAL ONCOLOGY, 2010, 22 (10) : 818 - 827
  • [48] New approach to target metastatic colorectal cancer organotropism with L-Annamycin
    Zielinski, Rafal J.
    Grela, Krzysztof Grela
    Cardenas-Zuniga, Roberto
    Skora, Stanislaw
    Fokt, Izabela
    Felix, Edward
    Grybowski, Damian
    Priebe, Waldemar
    CANCER RESEARCH, 2022, 82 (12)
  • [49] Tissue metabolite composition driving metastatic organotropism in prostate cancer: the role of asparagine
    Pranzini, E.
    Ippolito, L.
    Santi, A.
    Iozzo, M.
    Pardella, E.
    Salvatore, G.
    Gangarossa, G.
    Morandi, A.
    Comito, G.
    Giannoni, E.
    Chiarugi, P.
    FEBS OPEN BIO, 2024, 14 : 81 - 81
  • [50] The metabolic adaptation mechanism of metastatic organotropism
    Chao Wang
    Daya Luo
    Experimental Hematology & Oncology, 10